Evidence map›Paper›PMID 38443345›Full record

ArticleBlood cancer journal2024

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani and 11 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07094048 (Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager), which is not on this map. Cited by 83 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 13 pooled it
40.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07094048 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

TypeinterventionalSponsorCHU de Quebec-Universite LavalRan2026 to 2029Enrolled80ConditionsMultiple Myeloma Refractory, Relapsed Multiple MyelomaArmsTarget trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L
3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 13 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. T-Cell Engagers TargetingInternational journal of molecular sciences · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Review
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 1 country.

Meera Mohan *Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0002-6913-6526
Jorge Monge *Division of Hematology/Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-0854-0768
Nishi Shah *Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.ORCID 0000-0002-4723-6745
Danny LuanDivision of Hematology/Oncology, Weill Cornell Medicine, New York, NY, USA.
Mark ForsbergDivision of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.
Vineel BhatlapenumarthiDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Metodi BalevMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Anannya PatwariDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Heloise CheruvalathMedical College of Wisconsin Medical School, Milwaukee, WI, USA.
Divaya BhutaniMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Sharmilan ThanendrarajanMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Binod DhakalDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0002-4377-9742
Maurizio ZangariMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Samer Al-HadidiMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.ORCID 0000-0003-4297-8042
Dennis CooperDivision of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.
Suzanne LentzschMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Frits van RheeDivision of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0001-9959-1282
Anita D'SouzaDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Aniko SzaboDivision of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID 0000-0002-8129-0614
Carolina SchinkeMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.ORCID 0000-0002-2699-1741
Rajshekhar ChakrabortyMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA. rc3360@cumc.columbia.edu.ORCID 0000-0001-7336-3003
Medical College of Wisconsin · USUniversity of Arkansas for Medical Sciences · USAlbert Einstein College of Medicine · USAmyloidosis Foundation · USCornell University · USColumbia University Irving Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of teclistamab up until August 2023. One hundred and ten patients were included, of whom, 86% had triple-class refractory disease, 76% penta-refractory disease, and 35% had prior exposure to B-cell maturation antigen (BCMA)-targeting therapies. The overall response rate (ORR) in our cohort was 62%, with a ≥ very good partial remission (VGPR) rate of 51%. The ORR in patients with and without prior BCMA-targeted therapies was 54% vs 67%, respectively (p = 0.23). At a median follow-up of 3.5 months (range, 0.39-10.92), the estimated 3 month and 6 month progression free survival (PFS) was 57% (95% CI, 48%, 68%) and 52% (95% CI, 42%, 64%) respectively. The incidence of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) was 56% and 11% respectively, with grade ≥3 CRS and ICANS noted in 3.5% and 4.6% of patients respectively. 78 unique infections were diagnosed in 44 patients, with the incidence of all-grade and grade ≥3 infections being 40% vs 26% respectively. Primary prophylaxis with intravenous immunoglobulin (IVIG) was associated with a significantly lower infection risk on multivariate analysis (Hazard ratio [HR] 0.33; 95% CI 0.17, 0.64; p = 0.001).

Indexed as

Antibodies, BispecificAntineoplastic AgentsMultiple MyelomaNeoplasms, Plasma CellB-Cell Maturation AntigenHumansRetrospective StudiesAntibodies, BispecificAntineoplastic AgentsB-Cell Maturation Antigen

Identifiers

PMID38443345
PMCPMC10914756
OpenAlexW4392465169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.